635713-69-8

Basic information

• Product Name: 2-PHENYL-1.3.8-TRIAZA-SPIRO[4.5]DEC-1-EN-4-ONE HCL
• Synonyms: 2-PHENYL-1.3.8-TRIAZA-SPIRO[4.5]DEC-1-EN-4-ONE HCL;1,3,8-Triaza-spiro[4,5]dec-1-en-4-one hydrochloride;2-phenyl-1,3,8-Triazaspiro[4.5]dec-1-en-4-one
• CAS NO: 635713-69-8
• Molecular Formula: C₁₃H₁₅N₃O
• Molecular Weight: 229.28
• Mol File: 635713-69-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-PHENYL-1.3.8-TRIAZA-SPIRO[4.5]DEC-1-EN-4-ONE HCL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PHENYL-1.3.8-TRIAZA-SPIRO[4.5]DEC-1-EN-4-ONE HCL(635713-69-8)
• EPA Substance Registry System: 2-PHENYL-1.3.8-TRIAZA-SPIRO[4.5]DEC-1-EN-4-ONE HCL(635713-69-8)

Safety Data

• Hazardous Substances Data: 635713-69-8(Hazardous Substances Data)

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 151097-03-9 C₂₀H₂₁N₃O 
• 136624-42-5 4-amino-1-benzylpiperidine-4-carbonitrile 
• 865626-62-6 4-oxo-2-phenyl-1,3,8-triaza-spiro[4.5]dec-1-ene-8-carboxylic acid tert-butyl ester 
• 635713-70-1 4-benzoylamino-4-cyano-piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 943145-62-8 2-phenyl-1,3,8-triaza-spiro[4.5]dec-1-en-4-one, hydrochloride 
• 1384431-94-0 C₃₅H₄₂N₆O₃S 

Relevant articles and documents

Design and synthesis of potent antagonists containing rigid spirocyclic privileged structures for the CGRP receptor

We report the synthesis of rigid spirocyclic systems as conformationally constrained variants of the Ala-Phe-NH2 dipeptide amide C-terminus of the calcitonin gene-related peptide (CGRP). CGRP receptor antagonists containing these moieties displ

CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS

The presnt invention relates to compounds of Formula (I), as antagonists of calcitonin gene-related peptide receptors ("CGRP-receptor"), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.